Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: A randomized controlled trial (the RECORD study)
<p>Abstract</p> <p>Background</p> <p>Hypertension and type 2 diabetes are common co-morbidities. Preliminary studies suggest that thiazolidinediones reduce blood pressure (BP). We therefore used ambulatory BP to quantify BP lowering at 6–12 months with rosiglitazone use...
Main Authors: | Zambanini Andrew, Pocock Stuart J, Beck-Nielsen Henning, Hanefeld Markolf, Curtis Paula, Komajda Michel, Jones Nigel P, Gomis Ramon, Home Philip D |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2008-04-01
|
Series: | Cardiovascular Diabetology |
Online Access: | http://www.cardiab.com/content/7/1/10 |
Similar Items
-
One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes.
by: Hanefeld, M, et al.
Published: (2004) -
Diabetes mellitus in the young: Gliptins or sulfonylurea after metformin?
by: J Muthukrishnan, et al.
Published: (2012-01-01) -
Cognitive Function in Type 2 Diabetes Mellitus Patients Taking Metformin and Metformin-Sulfonylurea
by: Abu Rachman, et al.
Published: (2022-11-01) -
Efficacy of metformin versus sulfonylurea derivative in HNF4A-MODY
by: Nicole Oosterom, et al.
Published: (2022-01-01) -
Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes
by: Christina S. Kwon, et al.
Published: (2018-02-01)